Anisomycin

Anisomycin is a potent protein synthesis inhibitor which interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system^[1]. Anisomycin is a JNK activator, which increases phospho-JNK^[2][3]. Anisomycin is a bacterial antibiotic^[4]. IC50 & Target: DNA synthesis^[1] In Vitro: To examine whether JNK has a core role in colistin-induced neurotoxicity in PC-12 cells, an SP600125 (a highly selective inhibitor of JNK) and Anisomycin (a potent activator) are used in this study. In order to select an appropriate concentration, PC-12 cells are treated with a range of SP600125 (0-80 μM) and Anisomycin (0-20 μM) respectively for 24 h. The results show that the cells viability significantly decreases by SP600125 treatment in a concentration-dependent manner, observed at the concentrations greater than 20 μM (p<0.01). Similarly the cells viability is inhibited by Anisomycin treatment (≥8 μM) (p<0.05) ^[1]. In Vivo: Anisomycin (60 mg/kg; for 4-week continuous intravenous administration) significantly decreases mouse body weight in a dose-related manner, compared with the control group. Anisomycin (15 mg/kg; for 4-week continuous intravenous administration) slightly and transiently decreases the mouse body weight. There is no significant difference of the mouse body weight in 5 mg/kg group^[3].